Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.54 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260963 | 1.00 | LRRK2 (0.54) | LRRK2RPS6KA5MAP3K7TAB1CCNT1 | |
| Hydrochloric Acid SCHEMBL28274256 | 0.98 | LRRK2 (0.53) | LRRK2RPS6KA5MAP3K7TAB1CCNT1 | |
| SCHEMBL1799199 | 0.81 | RPS6KA5 (0.42) | LRRK2RPS6KA5CCNT1CDK9AAK1 | |
| SCHEMBL18789206 | 0.78 | LRRK2 (0.50) | LRRK2RPS6KA5CCNT1CDK9PRMT5 | |
| SCHEMBL1796396 | 0.76 | AAK1 (0.40) | LRRK2RPS6KA5CCNT1CDK9AAK1 | |
| SCHEMBL25401085 | 0.75 | CHUK (0.51) | LRRK2CHUK | |
| SCHEMBL5815182 | 0.74 | AAK1 (0.57) | LRRK2RPS6KA5AAK1 | |
| SCHEMBL31049378 | 0.71 | LRRK2 (0.51) | LRRK2CCNT1CDK9HASPINCHUK | |
| SCHEMBL1564211 | 0.71 | LRRK2 (0.51) | LRRK2CCNT1CDK9HASPINCHUK | |
| SCHEMBL3004634 | 0.71 | LRRK2 (0.51) | LRRK2CCNT1CDK9HASPINCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-02-29 | — | — | US | claimed |
| EP-4273149-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2023-11-08 | — | — | EP | claimed |
| CN-111527091-B | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2023-03-28 | — | — | CN | claimed |
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118119611-A | Small molecules for degradation of DOT1L and uses thereof | 丹娜-法伯癌症研究所 | 2024-05-31 | — | — | CN | disclosed |
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO INC. (KR) | 2023-06-15 | — | — | US | disclosed |
| CN-116003441-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115925705-A | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111527091-B | Oxy-fluoropiperidine derivatives as kinase inhibitors | 株式会社大熊制药 | 2023-03-28 | — | — | CN | disclosed |
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | VORONOIBIO CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183243-A1 | HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | TTK, TTBK1, TTBK2 | LRRK2 509/4885RPS6KA5 490/4885MAP3K7 153/4885 |
| US-20240067668-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | LRRK2 27/4885RPS6KA5 464/4885MAP3K7 515/4885 |
| US-20230066011-A1 | PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT | LRRK2, BRCA1, PARK7 | LRRK2 1/4885RPS6KA5 25/4885MAP3K7 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.